Small Study Links Oxaloacetate Supplement to Better Cognition After Breast Cancer Treatment

A small study offers an early signal that oxaloacetate, a dietary supplement, may ease cognitive complaints after breast cancer treatment. Among 18 early-stage breast cancer survivors who reported cognitive difficulties, 16 said their cognition improved during supplementation. Participants also reported less fatigue and better physical function. The findings are encouraging, but they don’t establish that oxaloacetate caused the changes or that it’s safe and effective for wider use.

Published in JCO Oncology Advances, the study focused on people who had completed treatment for early-stage breast cancer and were experiencing cognitive symptoms. The researchers tracked participants’ reports while they took oxaloacetate. Because the study included only 18 people and did not have a placebo comparison group, it can’t show how much of the reported improvement came from the supplement, or whether similar changes might have occurred without it.

Why researchers are studying these symptoms

Cognitive difficulties, often described as “brain fog,” can affect people during and after cancer treatment. They may involve problems with memory, attention or clear thinking. Patricia A. Ganz, M.D., a study author and cancer prevention and control researcher at UCLA Health’s Jonsson Comprehensive Cancer Center, said these symptoms affect an estimated 20% to 25% of breast cancer survivors. The source article notes that there are currently no medicines specifically designed to treat these complaints.

For patients, the effects can reach beyond concentration. In this study, participants also reported changes in fatigue, including mental fatigue, and physical functioning. The researchers noted improvement in insomnia as well. Those reports matter because symptoms that persist after treatment can affect daily life, yet the study’s size means the results should be treated as preliminary rather than as proof of a dependable benefit.

Oxaloacetate occurs naturally in the body. Researchers have proposed two ways it might affect cognition: it could help reduce excess glutamate, a chemical messenger involved in learning and memory that may build up in response to inflammation, and it could support energy production in cells. Cancer and its treatments may affect these processes. The proposed mechanisms remain uncertain, however; this study does not establish how oxaloacetate might work in people or confirm that either explanation accounts for the reported changes.

Interest in these possible effects extends to other conditions that involve similar symptoms. The source article points to research exploring oxaloacetate in connection with fatigue associated with long COVID. That broader interest does not establish a benefit for any condition, and results in one group of patients can’t be assumed to apply to another.

What the study can and can’t tell us

The main limitation is the lack of a placebo group. Without a comparison, researchers can’t separate a supplement’s effect from other influences, such as natural changes in symptoms or participants’ expectations. Ganz said the true improvement may be more modest than participants’ reports suggest. Her team plans to test oxaloacetate in a future study with a placebo comparison.

The study also doesn’t settle questions about possible harms. Side effects of oxaloacetate may not yet be fully understood. Larry Norton, M.D., a breast medical oncologist at Memorial Sloan Kettering, said that assessing whether a treatment’s benefits outweigh its downsides requires a well-established process, which has not yet been completed for this compound. Ganz said the supplement can’t currently be recommended for these symptoms, despite the encouraging findings.

That caution is particularly relevant for people receiving cancer care, who may be taking other medicines or managing treatment effects. A supplement’s availability doesn’t show that it has been adequately tested for a particular use. Anyone considering one can discuss it with their cancer care team or pharmacist, including possible side effects and interactions. The study provides no basis for changing prescribed treatment.

Brain fog deserves a careful assessment

There can be many reasons for cognitive changes. Norton said that cancer treatments are one possible factor, but medicines and procedures such as anesthesia can also affect thinking. Other issues—including anemia, sleep problems, depression and changes in thyroid function—may produce similar symptoms and could be treatable. Stress and aging may contribute, too. A clinician can help assess what might be involved instead of assuming that every change is caused by cancer treatment.

Some cancer medicines are more likely than others to affect brain function, Norton said, and brain imaging may sometimes show changes. At the same time, cognitive effects aren’t inevitable. Many people receive cancer treatment without these problems, and when medicine-related changes occur, they’re often mild and temporary, he said. Concern about possible cognitive effects alone should not lead someone to avoid treatment that their care team believes may be lifesaving.

For day-to-day difficulties, Norton described practical memory supports such as lists, smartphone reminders and labels on objects. Saying an action aloud—for example, where keys are being placed or that a door is being locked—may also help reinforce it. He also pointed to exercise, including yoga, outdoor walks or using an exercise bicycle, as a potential aid. These strategies don’t identify the cause of symptoms, so persistent or troubling changes still merit discussion with a clinician.

What patients can take from the findings

The study adds an early clue that oxaloacetate may be worth examining as researchers look for ways to address cognitive symptoms after breast cancer treatment. It does not show that the supplement is ready for routine use, and it leaves open both the size of any benefit and the possibility of side effects. A larger study with a placebo group is needed to clarify those questions.

For now, people experiencing brain fog can tell their care team what they’re noticing and when it began. Sleep difficulties or depressive symptoms, for example, may be treatable and may contribute to cognitive complaints. Norton emphasized that patients’ symptoms should be taken seriously and addressed as part of their care, not left out of conversations focused on treating cancer.

Dietary supplements are intended to supplement the diet; they aren’t medicines and aren’t intended to treat, diagnose, prevent or cure disease. The most useful next step from this research is further testing. For patients, the immediate takeaway is to report cognitive changes and work with their care team to consider possible causes and available ways to manage them.